NFE2L2 and fatty liver disease: Further analysis revealed that mutations in Cys288 and Arg415 inhibited VPA-induced NRF2 nuclear translocation and FATP2 expression to varying degrees (Figure 6L) and significantly improved hepatic steatosis (Figure 6M, N).